SCHEMBL742343

SCHEMBL742343

COc1ccc(CCNC(=O)C(c2ccccc2)c2ccccc2)cc1OC

nearest known ligand 0.71

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 5/20 0.71
MEN1 O00255 3/20 0.71
ALDH1A1 P00352 4/20 0.64
ADRB2 P07550 1/20 0.60
CA12 O43570 1/20 0.60
CA1 P00915 1/20 0.60
CA2 P00918 1/20 0.60
CA9 Q16790 1/20 0.60
PLAAT3 P53816 1/20 0.60
PLAAT5 Q96KN8 1/20 0.60
PLAAT2 Q9NWW9 1/20 0.60
PLAAT4 Q9UL19 1/20 0.60
MAPT P10636 1/20 0.60
MAPK1 P28482 1/20 0.59
NPSR1 Q6W5P4 1/20 0.59
HPGD P15428 1/20 0.59
ALOX12 P18054 1/20 0.59
SMN1; SMN2 Q16637 1/20 0.59
GAA P10253 1/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8098635 0.89 ALDH1A1 (0.62) KMT2AMEN1ALDH1A1ADRB2CA12
SCHEMBL6094268 0.89 ALDH1A1 (0.62) KMT2AMEN1ALDH1A1ADRB2CA12
SCHEMBL20418416 0.88 ALDH1A1 (0.61) KMT2AMEN1ALDH1A1ADRB2CA12
SCHEMBL8428854 0.88 ALDH1A1 (0.61) KMT2AMEN1ALDH1A1ADRB2CA12
SCHEMBL11509318 0.88 ALDH1A1 (0.61) KMT2AMEN1ALDH1A1ADRB2CA12
SCHEMBL6376353 0.86 POLB (0.68) KMT2AMEN1ALDH1A1ADRB2CA12
SCHEMBL10690654 0.84 KMT2A (0.59) KMT2AMEN1ALDH1A1ADRB2CA12
SCHEMBL8107748 0.83 HTT (0.57) KMT2AMEN1ALDH1A1ADRB2CA12
SCHEMBL2778736 0.83 ALDH1A1 (0.57) KMT2AMEN1ALDH1A1ADRB2CA12
SCHEMBL8428857 0.83 ALDH1A1 (0.56) KMT2AMEN1ALDH1A1ADRB2CA12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3079680-A2 COMPOSITIONS AND METHODS FOR TREATING, PREVENTING AND DIAGNOSING CANCER AND OTHER PROLIFERATIVE DISORDERS Angiogenex, Inc. (US) 2016-10-19 EP disclosed
WO-2015089495-A2 COMPOSITIONS AND METHODS FOR TREATING, PREVENTING AND DIAGNOSING CANCER AND OTHER PROLIFERATIVE DISORDERS ANGIOGENEX, INC. (US) 2015-06-18 WO disclosed
US-8138356-B2 Chemical inhibitors of inhibitors of differentiation Angiogeney, Inc. (US) 2012-03-20 US disclosed
US-20090226422-A1 Chemical Inhibitors of Inhibitors of Differentiation ANGIOGENEX 2009-09-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090226422-A1 Chemical Inhibitors of Inhibitors of Differentiation BRAF, MAPK1, RAF1 KMT2A 3273/4885MEN1 3968/4885ALDH1A1 1860/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.